ASH 2022 | Phase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL
Parag Jasani
• 10 Dec 2022
Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College London Hospital, London, UK, briefly summarizes preliminary data from a Phase I trial evaluating a ROR1xCD3 bispecific T-cell engager (BiTE) as monotherapy or in combination with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL; NCT04763083). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
